Abstract
Garcinia mangostana L.has been used as an antioxidant to inhibit oxidation of low density lipoproteins and as an antiobesity agent. The aim of this study was to evaluate the effect of a Mangosteen (G. mangostana L.) Pericarp Ethanolic Extract (MPEE) on lipid profile in rats fed with high-fat diet.The experimental study was conducted in male Wistar rats for 4 weeks and 9 weeks, with rats divided into 5 treatment groups which were normal (standard diet), control (high-fat diet), dose 1 (high-fat diet, MPEE 200 mg/kg b.w.), dose 2 (high-fat diet, MPEE 500 mg/kg b.w.), and orlistat (high-fat diet, orlistat 21.6 mg/kg b.w.) groups. The serum concentration of cholesterol High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL) and triglycerides of all the animals in each group were determined after the 4 weeks and 9 weeks of treatment. Intrygliceride level, MPEE at the dose of 500 mg/kgbw was more active than the dose of 200mg/kg. The rats treated with MPEE significantly decreased the LDL level in the 9 weeks at the dose of 200 mg/kg bw and 500 mg/kg bw. However, the HDL level amongthe all groups showed no significant difference.Mangosteen Pericarp Ethanolic Extract (MPEE) has potential as anti-obesity drugs by lowering the tryglyceride and LDL level in high-fat Wistar rats.
Highlights
Obesity is well-known to contribute to the health impairment and several diseases such as work disability, sleep apnea, cardiovascular disease, cancer, type 2 diabetes mellitus, and osteoarthritis[1]
One of the metabolic defects to appear in obese individuals, which is central to the pathway of Atherosclerotic Cardiovascular Diseases (ASCVD) is, dyslipidemia[3,4]
An imbalance between caloric intake and energy expenditure results in excessive storage of corporal fat, often resulting in overweight or obesity. This imbalance often produces an altered lipid profile characterized by high triglycerides (TG) serum levels, high total cholesterol, high LowDensity Lipoprotein (LDL)-cholesterol, and low levels of High Density Lioprotein (HDL)-cholesterol that increases the risk of cardiovascular disease (CAD)[20]
Summary
Obesity is well-known to contribute to the health impairment and several diseases such as work disability, sleep apnea, cardiovascular disease, cancer, type 2 diabetes mellitus, and osteoarthritis[1]. It was estimated that 3.4 million deaths in the year 2010 were caused by overweight and obesity[2]. Obesity could lead to the decrease of life quality. Obesity is associated with several established Atherosclerotic Cardiovascular Diseases (ASCVD) risk factors. One of the metabolic defects to appear in obese individuals, which is central to the pathway of ASCVD is, dyslipidemia[3,4]. Dyslipidemia is one of the most prevalentmetabolic impairments in obesity, occurring in almost 60% of abdominally obese subjects, and one of the strongest ASCVD risk factors in obesity[3,4,5]. The prevention and treatments for obesity are urgently needed[1,2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
